Pharmacy benefit design options available to employers

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 2, Issue 4, 2002, Pages 389-396

  Encinosa, William E ^a  

^a AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

Author keywords

Drug costs; Drug plans; Pharmacy benefit design; Prescription drug copayments; Reference pricing

Indexed keywords

AMFEBUTAMONE; ANTIHYPERTENSIVE AGENT; BUSPIRONE; CELECOXIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESOMEPRAZOLE; FEXOFENADINE; FLUOXETINE; GENERIC DRUG; LORATADINE; NAPROXEN; ROFECOXIB; SILDENAFIL;

CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; DRUG FORMULARY; EMPLOYEE; EMPLOYER; HUMAN; INSURANCE; PHARMACY; REVIEW;

EID: 0036045794     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.2.4.389     Document Type: Review

References (38)

1. Consumer-directed healthcare
2. Soon we'll all be paying more for drugs
3. Recent patterns of medication use in the ambulatory adult population of the United States
4. Survey Findings: Healthcare Expenditures: Future Strategy and Direction 2002
5. Kaiser/HRET Survey of Employer-Sponsored Health Benefits: 2001
6. Novartis Pharmacy Benefit Report: Facts and Figures 2001
7. A Primer: Generic Drugs, Patents and the Pharmaceutical Marketplace
8. Prescription Drug Expenditures in 2001: Another year of Escalating Costs
9. Tech Trader: FTC Looks at Pharmaceutical Deals
10. Drug coverage decisions: The role of dollars and values
11. Out-patient prescription drug prices and insurance coverage: An anlysis by therapeutic drug class and user characteristics from 1996 medical panel survey
12. Pharmacy Benefits: New Concepts in Plan Design-Private Sector Employer Perspectives
13. Novartis Managed Care Pharmacy Benefit Facts and Figures: Market Place Trends 2000
14. Financial incentives and drug spending in managed care
15. The impact of benefit design on prescription drug spending
16. Effect of a threetier prescription copay on pharmaceutical and other medical utilization
17. Pharmacy benefits: New concepts in plan design
18. Strategies to improve the cost effectiveness of general practitioner prescribing: An international perspective
19. The medicare prescription drug benefit: How will the game be played?
20. Review of the Literature on Reference Pricing. Health Policy
21. Outcomes of reference pricing for angiotensis-converting-enzyme inhibitors
22. Do pharmaceutical prices respond to insurance?
23. Utilization of essential medications by vulnerable older people after a drug benefit cap: Importance of mental disorders, chronic pain and practice setting
24. Defined-contribution health insurance products: Development and prospects
25. Employer-sponsored health insurance: Pressing problems, incremental changes
26. New Health Plans Turn Patients into Shoppers
27. Giving Power to the Patient
28. Designing employer health benefits for heterogeneous workforces: Risk adjustment and its alternatives
29. A benefit-based copay for prescription drugs: Patient contribution based on total benefits, not drug acquisition cost
30. Optimal health insurance: The case of multiple treatment options
31. Pharmacy benefit management companies: Dimensions of performance
32. Medco finds ties that bind-contract with Merck compels pharmacy-benefits manager to push parent company's drugs
33. Drug Prices-Why They Keep Soaring-Swallow This: How Drug Makers Use Pharmacies to Push Pricey Pills
34. Employers: Quality Takers or Quality Makers